伊贝沙坦治疗轻中度原发性高血压的疗效和安全性  

Efficacy and safety of irbesartan in patients with mild to moderate essential hypertension

作　　者：王云[1] 柯元南[1] 钱端[2] 杨屹云[1] 姜红[1] 

机构地区：[1]中日友好医院心内科,北京100029 [2]中日友好医院高干医疗科,北京100029

出　　处：《中日友好医院学报》2005年第1期3-5,共3页Journal of China-Japan Friendship Hospital

摘　　要：目的:观察伊贝沙坦治疗轻中度原发性高血压的疗效和安全性。方法:采用随机双盲平行对照试验的方 法。将符合条件的轻中度原发性高血压患者65例随机分为伊贝沙坦组和贝那普利组。每天一次口服伊贝沙 坦150mg或贝那普利10mg,疗程共8周。结果:(1)治疗8周后,伊贝沙坦组降压总有效率75%,贝那普利组 总有效率68.8%,两组无统计学差异(P<0.05)。(2)治疗前后收缩压、舒张压下降幅度分别为:伊贝沙坦组 11.4%和12.6%,贝那普利组8.8%和11.0%,无统计学差异(P>0.05)。(3)不良反应的发生率,伊贝沙坦组 为3.1%,贝那普利组为15.2%,二者有显著性差异(P<0.05)。常见的不良反应有咳嗽、头晕等。结论:伊贝 沙坦150mg/d治疗轻中度原发性高血压安全有效,不良反应发生率低于贝那普利。Objective:To observe the efficacy and safety of irbesartan in patients of essential hypertension.Methods:this study was a randomized,double blind and parallel controlled trial.65 eligible mild and moderate hypertension patients were divided randomly into irbesatan group and benazepril group.150 mg of irbesatan or 10mg of benazepril was administrated once per day, and the patients were followed up in every two weeks. This trial was continued for 8 weeks.Results:(1) After 8 weeks, the rate of effectiveness of irbesatan and benazepril were 75% and 68.8% respectively,there were no significant difference between the 2 groups.(2) After 8 weeks, the SBP and DBP of irbesatan group decreased 11.4% and 12.6%,benazepril group decreased 8.8% and 11.0% and no significant difference was observed.(3) The side effects ratio was significantly lower in irbesatan group(3.1%) than that in benazepril group(15.2%).The most common side effects were cough and mild dizziness.Conclusion:Irbesartan(150 mg/d) is effective、safe and well tolerated in the treatment of mild to moderate essential hypertension.

关 键 词：伊贝沙坦 贝那普利 高血压 

分 类 号：R544.1[医药卫生—心血管疾病]